Viatris (VTRS) EBT Growth (1y) (2020 - 2026)
Viatris (VTRS) EBT Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 48.64% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | -1.94% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -393.93% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -24.84% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 92.01% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 1,578.91% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 45.00% |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 12.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.01% |
| Dec 31, 2025 | 34.85% |
| Sep 30, 2025 | -108.73% |
| Jun 30, 2025 | 44.59% |
| Mar 31, 2025 | -1,613.69% |
| Dec 31, 2024 | 38.42% |
| Sep 30, 2024 | -77.50% |
| Jun 30, 2024 | -217.66% |
| Mar 31, 2024 | -36.60% |
| Dec 31, 2023 | -158.21% |
| Sep 30, 2023 | -5.92% |
| Jun 30, 2023 | -14.46% |
| Mar 31, 2023 | -38.82% |
| Dec 31, 2022 | 820.40% |
| Sep 30, 2022 | 113.86% |
| Jun 30, 2022 | 277.68% |
| Mar 31, 2022 | 219.53% |
| Dec 31, 2021 | 79.88% |
| Sep 30, 2021 | 190.45% |
| Jun 30, 2021 | -18,158.33% |